Targeting the TAM Receptors in Leukemia

Por Huey, Madeline G., Minson, Katherine A., Earp, H. Shelton, DeRyckere, Deborah, Graham, Douglas K.
Publicado no Cancers (Basel) (2016)

UNC2025, a MERTK small molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models

Por DeRyckere, Deborah, Lee-Sherick, Alisa B., Huey, Madeline G., Hill, Amanda A., Tyner, Jeffrey W., Jacobsen, Kristen M., Page, Lauren S., Kirkpatrick, Gregory G., Eryildiz, Fatma, Montgomery, Stephanie A., Zhang, Weihe, Wang, Xiaodong, Frye, Stephen V., Earp, H. Shelton, Graham, Douglas K.
Publicado no Clin Cancer Res (2016)

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia

Por Minson, Katherine A., Smith, Catherine C., DeRyckere, Deborah, Libbrecht, Clara, Lee-Sherick, Alisa B., Huey, Madeline G., Lasater, Elisabeth A., Kirkpatrick, Gregory D., Stashko, Michael A., Zhang, Weihe, Jordan, Craig T., Kireev, Dmitri, Wang, Xiaodong, Frye, Stephen V., Earp, H. Shelton, Shah, Neil P., Graham, Douglas K.
Publicado no JCI Insight (2016)

Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae

Por Grace, Peter M., Ramos, Khara M., Rodgers, Krista M., Wang, Xiaohui, Hutchinson, Mark R., Lewis, Makenzie T., Morgan, Kelly N., Kroll, Juliet L., Taylor, Frederick R., Strand, Keith A., Zhang, Yingning, Berkelhammer, Debra, Huey, Madeline G., Greene, Lisa I., Cochran, Thomas A., Yin, Hang, Barth, Daniel S., Johnson, Kirk W., Rice, Kenner, Maier, Steven F., Watkins, Linda R.
Publicado no Neuroscience (2014)